South Korea’s Samsung Group is in negotiations to buy Biogen, a leading US-based drugmaker for neurological diseases such as Alzheimer’s and dementia, Korea Economic Daily reported.
The Nasdaq-listed biotechnology firm approached Samsung to sell its shares, which could be valued at more than 50 trillion won ($42 billion).
Read the full report: Korea Economic Daily.
Samsung to Merge Mobile, Consumer Electronics Units
Samsung To Supply Advanced Auto Chips To Volkswagen
Samsung To Pick Taylor, Texas, For $17bn Chip Plant: WSJ